blew past first-quarter earnings estimates early Thursday, while raising its full-year outlook by a smaller amount. The pharmacy and health benefits giant also announced an agreement to make Novo Nordisk's (NVO) Wegovy its preferred GLP-1 obesity medication. CVS stock is sharply higher,…